Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

A function for sleep-dependent tau dynamics

sleepyTau

Dysfunction of protein Tau is the main cause of dementia. Dementia associates with synaptic failure and sleep disturbances, but their connection remains elusive. In dementia, Tau becomes hyperphosphorylated (p-Tau) causing synaptic loss. Temperature fluctuations also associate with Tau phosphorylation, for example in hibernating animals...

Funding Programme
Start Date
End Date
Total Funding
€ 175 920
European Countries Involved

a toolkit for dynaMic health Impact analysiS to predicT disability-Related costs in the Aging population based on three case studies of steeL-industry exposed areas in europe

MISTRAL

The environment is one of the most crucial determinants of health. The Global Burden of Disease report estimates an emerging impact in terms of disability and reducing the quality of life worldwide, particularly for the aging populations. One of the root causes of this decline is likely to derive from the interaction of socio-environmental risk...

Funding Programme
Start Date
End Date
Total Funding
€ 3 619 635
European Countries Involved

affecTive basEd iNtegrateD carE for betteR Quality of Life

TeNDER

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease...

Funding Programme
Start Date
End Date
Total Funding
€ 5 698 333
European Countries Involved

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...

Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer Disease - gut connection

AD-gut

Alzheimer’s disease (AD) is the leading cause of dementia in the Western world and to date no cure nor any preventive strategy are available for this neurodegenerative disorder. Bacterial 16S rRNA sequencing from fecal samples revealed a remarkable shift in the gut microbiota of conventionally-raised AD mice compared to healthy, wild-type mice...

Funding Programme
Start Date
End Date
Total Funding
€ 7 686 620
European Countries Involved

Alzheimer's Disease (AD) Detect & Prevent - Presymptomatic AD detection and prevention

AD Detect-Prevent

Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable...

Funding Programme
Start Date
End Date
Total Funding
€ 3 880 990
European Countries Involved

Alzheimer's disease apolipoprotein pathology for treatment elucidation and development

ADAPTED

Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well...

Funding Programme
Start Date
End Date
Total Funding
€ 6 796 740
European Countries Involved

Alzheimer’s disease and AAV9: Use of a virus-based delivery system for vectored immunoprophylaxis in dementia.

AD-VIP

Alzheimer’s disease (AD) is the most common form of dementia in the Western World, representing an economic and social cost of billions of euros a year. Given the changing demographics of society, these costs will only increase over the coming decades.Amyloid plaques, composed of amyloid beta peptide (Abeta), are a defining characteristic of AD...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Amyloid imaging to Prevent Alzheimer’s Disease

AMYPAD

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive...

Funding Programme
Start Date
End Date
Total Funding
€ 27 329 288

ARTIFICIAL INTELLIGENCE BASED HEALTH, OPTIMISM, PURPOSE, AND ENDURANCE IN PALLIATIVE CARE FOR DEMENTIA

AI4HOPE

Dementia is caused by a range of illnesses and disorders that damage the brain either directly or indirectly. With the rise of the ageing population in the EU, dementia is becoming a serious problem. Digital health interventions have the potential to improve the accessibility and effectiveness of palliative care. Palliative care is an area where...

Funding Programme
Start Date
End Date
Total Funding
€ 6 419 025

Brain barriers training

BtRAIN

The brain barriers function to protect the central nervous system (CNS) from neurotoxic compounds. By the same traits they unfortunately block delivery of drugs to the CNS thus hindering proper diagnosis and effective treatment of neurological disorders including Alzheimer’s disease and multiple sclerosis. The unusual complexity of the brain...

Funding Programme
Start Date
End Date
Total Funding
€ 3 067 402

CARELINK for People with Dementia and their community

CARE-LINK

The objective of CARELINK is to deliver a tracking solution that addresses the issue of wandering in People with Dementia (PwD), allowing carers to monitor PwD. Using current machine-learning technologies we will profile user routes that can then be used to build a repository of route patterns to be compared against live routes, thus allowing for...

Funding Programme
Start Date
End Date
Total Funding
€ 2 282 944
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).